Chapter: Severe Asthma

1. Assess the interventions that optimize the inhaled delivery of pharmacologic therapy in patients with difficult-to-treat and severe asthma.
2. Assess the use of biomarkers in difficult-to-treat and severe asthma.
3. Distinguish between the pharmacologic agents available for the treatment of severe asthma.
4. Design a pharmacologic treatment regimen that incorporates updated evidence-based asthma guidelines and patient-specific characteristics.
5. Evaluate factors that affect the assessment and treatment of patients with difficult-to-treat and severe asthma. 

Chapter: Allergic Rhinitis

1. Evaluate key differences in therapeutic recommendations from practice guidelines by leading expert groups.
2. Distinguish the role and place in therapy of antihistamines in the management of allergic rhinitis (AR).
3. Distinguish the role and place in therapy of leukotriene receptor antagonists (LTRAs).
4. Assess the use of combination intranasal corticosteroids and intranasal antihistamines in managing AR.
5. Distinguish the role and place in therapy of intranasal decongestants.
6. Assess the use of subcutaneous allergy and sublingual immunotherapy in AR.
7. Assess the use of acupuncture and herbal medications in therapy for AR. 

Chapter: Cystic Fibrosis

1. Describe the pathophysiology and genetic dysfunction of cystic fibrosis.
2. Analyze the efficacy and safety of current therapies for the chronic management of cystic fibrosis (CF), including CF transmembrane conductance regulator (CFTR) modulators.
3. Evaluate the progress made in the chronic medication management of CF, including the selection, use, and monitoring of CFTR modulators.
4. Evaluate people with CF (PwCF) experiencing pulmonary exacerbations, and determine the appropriate antibiotic dosing and monitoring plan for the treatment of the most common pathogens (prevalence greater than 10% PwCF).
5. Identify common barriers for PwCF to treatment adherence and access.
6. Explain the role of pharmacists in the care of PwCF, including strategies to improve adherence and access. 

Chapter: Pneumonia

1. Identify diagnostic workup necessary for differentiating bacterial pneumonia versus alternative causes.
2. Classify types of pneumonia based on clinical presentation, diagnostics, and overall hospitalization characteristics.
3. Evaluate patient risk factors for bacterial pneumonia secondary to multidrug resistant bacterial pathogens based on patient comorbidities, prior culture data, and local epidemiology.
4. Design a treatment regimen for a patient presenting to an acute care hospital with suspected or confirmed pneumonia secondary to bacteria, common respiratory viruses, or endemic mycoses.
5. Evaluate clinical response and patient-specific characteristics to guide duration of pneumonia-directed therapy.
6. Develop a preventative plan for patients considered at high-risk for pneumonia and/or pneumonia-related complications. 

Chapter: Inflammatory Bowel Disease

1. Distinguish between Crohn’s disease (CD) and ulcerative colitis (UC) and explain treatment goals.
2. Design a treatment regimen that incorporates current evidence and patient-specific characteristics for the management of acute severe UC.
3. Design a treatment regimen that incorporates current evidence and patient-specific characteristics for the management of CD-related complications.
4. Assess other conditions related to inflammatory bowel disease (IBD) that warrant management and monitoring.
5. Develop a plan for a patient with IBD transitioning from inpatient to outpatient. 

Chapter: Drug-Induced Liver Injury

1. Evaluate medication regimens likely to be associated with drug-inducedfulmin liver injury (DILI).
2. Differentiate between intrinsic, idiosyncratic, indirect, and hepatocellular DILI versus cholestatic DILI on the basis of patient history and laboratory data.
3. Design a patient-specific treatment and monitoring plan for DILI on the basis of the suspected causative agent.
4. Apply guideline recommendations for detecting DILI in clinical trials and postmarketing surveillance. 

Chapter: Medication Use after Bariatric Surgery

1. Distinguish appropriate and inappropriate medications used after bariatric surgery.
2. Design a plan for treatment or prevention of vitamin deficiencies seen in patients after bariatric surgery.
3. Design a plan for treatment or prevention of complications in patients during bariatric surgery.
4. Resolve drug therapy problems associated with medications after bariatric surgery.
5. Assess disease states that benefit from bariatric surgery. 

Interactive Case: Eosinophilic Esophagitis

1. Evaluate factors that affect the assessment and monitoring of patients with eosinophilic esophagitis (EoE).
2. Distinguish between available and investigational pharmacologic and biologic agents for the treatment of EoE.
3. Design a patient-specific treatment plan for EoE according to the latest AGA/JTF evidencebased guidelines. 

Interactive Case: Pancreatitis

1. Evaluate patients for the etiology, pathophysiology, and risk factors associated with acute pancreatitis (AP) and chronic pancreatitis (CP).
2. Assess the severity of AP and CP in the clinical presentation (i.e., patient history, symptoms, laboratory values, and imaging) of a patient with AP and CP.
3. Develop an evidence-based, patient-specific plan for the treatment of AP and CP.

Recorded Webcast: Vaping

1. Evaluate patients for the etiology, pathophysiology, and risk factors associated with acute pancreatitis (AP) and chronic pancreatitis (CP).
2. Assess the severity of AP and CP in the clinical presentation (i.e., patient history, symptoms, laboratory values, and imaging) of a patient with AP and CP.
3. Develop an evidence-based, patient-specific plan for the treatment of AP and CP.